With the dilemma of limited efficacy of individual therapies, it is crucial to develop innovative combination therapy systems to target the complex pathogenesis of cancer. In this study, we designed a nanoprodrug ISL@MIL-101-ADT to facilitate synergistic delivery of hydrogen sulfide (HS) and prodrug ISL for specific eradication of tumor cells with minimal toxicity and maximal efficacy. The nanoprodrug passively targeted tumors through enhanced permeation and retention effects, followed by disintegration and release of IR780, lonidamine (LND), and HS. IR780 localizes LND to mitochondria to enhance therapeutic effects and turn on the phototherapy and chemotherapy when exposed to a laser; HS inhibits procancer signaling pathways and mitochondrial function. In vivo experiments have demonstrated that ISL@MIL-101-ADT exhibits excellent pharmacokinetic properties and significant tumor inhibitory effects. Additionally, this nanoprodrug possesses outstanding photothermal and fluorescence imaging capabilities. Therefore, we strongly believe that the nanoprodrug present herein holds great potential for application in cancer therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.4c02426DOI Listing

Publication Analysis

Top Keywords

hydrogen sulfide
8
nanoprodrug
5
synthesis application
4
application novel
4
novel multifunctional
4
multifunctional nanoprodrug
4
nanoprodrug synergistic
4
synergistic chemotherapy
4
chemotherapy phototherapy
4
phototherapy hydrogen
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!